Integrative evaluation of primary and metastatic lesion spectrum to guide anti-PD-L1 therapy of non-small cell lung cancer: results from two randomized studies
Si-Cong Ma, Xin-Ran Tang, Li-Li Long, Xue Bai, Jian‐Guo Zhou, Zhijiao Duan, Jian Wang, Qiang Fu, Hongbo Zhu, Xue‐Jun Guo, Yan-Pei Zhang, Ze-Qin Guo, Dehua Wu, Zhong‐Yi Dong
Abstract
: The response to anti-PD-L1 therapy among patients varied with the primary and metastatic lesion spectrum. The DSO-based system might provide promising medication guidance for ICB treatment in NSCLC patients.
Topics & Concepts
AtezolizumabDocetaxelMedicineOncologyInternal medicineLung cancerChemotherapyLesionClinical trialCancerNivolumabImmunotherapySurgeryCancer Immunotherapy and BiomarkersLung Cancer Treatments and MutationsCancer, Stress, Anesthesia, and Immune Response